We herein present an overview of the upcoming 5 th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in …

Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates and …

Activation of NF-κB has been noted in many tumor types, however only rarely has this been
linked to an underlying genetic mutation. An integrated analysis of high-density …

Background Bortezomib with dexamethasone is a standard treatment option for relapsed or
refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity …

The International Myeloma Working Group consensus updates the definition for high-risk (HR)
multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14…

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven
malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …

The International Myeloma Working Group consensus aimed to provide recommendations
for the optimal use of 18 fluorodeoxyglucose ( 18 F-FDG) PET/CT in patients with multiple …

RNA modifications, such as N 6 -methyladenosine (m 6 A), modulate functions of cellular
RNA species. However, quantifying differences in RNA modifications has been challenging. …

Colorectal cancer (CRC) is one of the most common malignancies with high prevalence
and low 5-year survival. CRC is a heterogeneous disease with a complex, genetic and …